Last reviewed · How we verify

Dabigatran etexilate (DE) — Competitive Intelligence Brief

Dabigatran etexilate (DE) (dabigatran-etexilate-de) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dabigatran etexilate (DE) as oral capsule. Area: Cardiovascular.

discontinued Dabigatran etexilate (DE) as oral capsule Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone] Cardiovascular Live · refreshed every 30 min

Target snapshot

Dabigatran etexilate (DE) (dabigatran-etexilate-de) — Pfizer Inc.. Dabigatran etexilate (DE) as oral capsule

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dabigatran etexilate (DE) TARGET dabigatran-etexilate-de Pfizer Inc. discontinued Dabigatran etexilate (DE) as oral capsule Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dabigatran etexilate (DE) as oral capsule class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dabigatran etexilate (DE) — Competitive Intelligence Brief. https://druglandscape.com/ci/dabigatran-etexilate-de. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: